The potential of lifestyle changes for improving the clinical outcome of patients with coronary heart disease: Mechanisms of benefit and clinical results

Reviews on Recent Clinical Trials

Volumn 5, Issue 1, 2010, Pages 1-13

  Scrutinio, Domenico ^a  

^a IRCCS   (Italy)

Author keywords

Coronary heart disease; Secondary prevention; Therapeutic lifestyle changes

Indexed keywords

ARTICLE; AUTONOMIC NERVOUS SYSTEM; DIETARY INTAKE; HEART MUSCLE ISCHEMIA; HUMAN; INFLAMMATION; ISCHEMIC HEART DISEASE; LIFESTYLE MODIFICATION; MORBIDITY; MORTALITY; OBESITY; OUTCOME ASSESSMENT; PHYSICAL ACTIVITY; PRIORITY JOURNAL; RISK BENEFIT ANALYSIS; RISK FACTOR; SMOKING CESSATION; THROMBOGENESIS; CLINICAL TRIAL; CORONARY ARTERY DISEASE; DIET; EVIDENCE BASED MEDICINE; LIFESTYLE; MOTOR ACTIVITY; PATHOLOGY; REVIEW; SECONDARY PREVENTION; VASCULAR ENDOTHELIUM;

CLINICAL TRIALS AS TOPIC; CORONARY DISEASE; DIET; ENDOTHELIUM, VASCULAR; EVIDENCE-BASED MEDICINE; HUMANS; INFLAMMATION; LIFE STYLE; MOTOR ACTIVITY; OBESITY; RISK FACTORS; SECONDARY PREVENTION; SMOKING CESSATION;

EID: 77954715157     PISSN: 15748871     EISSN: None     Source Type: Journal    
DOI: 10.2174/157488710790820508     Document Type: Article

References (141)

1. Kotseva K, Wood D, De Backer G, et al. Cardiovascular preven-tion guidelines in daily practice: a comparison of EUROASPIRE I, II, and III surveys in eight European countries. Lancet 2009; 373: 929-40.
2. Kotseva K, Wood D, De Backer G, De Bacquer D, Pyörälä K, Keil U. EUROASPIRE III: a survey on the lifestyle, risk factors and use of cardioprotective drug therapies in coronary patients from 22 European countries. Eur J Cardiovasc Prev Rehabil 2009; 16: 121-37.
3. Wood DA, Kotseva K, Connolly S, et al. EUROACTION Study Group. Nurse-coordinated multidisciplinary, family-based cardio-vascular disease prevention programme (EUROACTION) for pa-tients with coronary heart disease and asymptomatic individuals at high risk of cardiovascular disease: a paired, cluster-randomised controlled trial. Lancet 2008; 371: 1999-2012.
4. Iestra JA, Kromhout D, van der Schouw YT. Grobbee DE, Boshui-zen HC, van Staveren WA. Effect size estimates of lifestyle and dietary changes on all-cause mortality in coronary artery disease patients: a systematic review. Circulation 2005; 112: 924-34.
5. Balady GJ, Williams MA, Ades PA, et al. Core components of cardiac rehabilitation/secondary prevention programs: 2007 update: a scientific statement from the American Heart Association Exer-cise, cardiac rehabilitation, and prevention committee, the council on Clinical Cardiology; the Councils on Cardiovascular Nursing, Epidemiology and Prevention, and Nutrition, Physical Activity, and Metabolism; and the American Association of Cardiovascular and Pulmonary Rehabilitation. Circulation 2007; 115: 2675-82.
6. Wenger NK. Current status of cardiac rehabilitation. J Am Coll Cardiol 2008; 51: 1619-31.
7. Franklin BA, Trivax JE, Vanhecke TE. New Insights in preventive cardiology and cardiac rehabilitation. Curr Opin Cardiol 2008; 23: 477-86.
8. Taylor RS, Brown A, Ebrahim S, et al. Exercise-based rehabilita-tion for patients with coronary heart disease: a systematic review and meta-analysis of randomized trials. Am J Med 2004; 116: 682-97.
9. Clark AM, Hartling L, Vandermeer B, McAlister FA. Meta-analysis: secondary prevention programs for patients with coronary artery disease. Ann Int Med 2005; 143: 659-72.
10. Witt BJ, Jacobsen SJ, Weston SA, et al. Cardiac rehabilitation after myocardial infarction in the community. J Am Coll Cardiol 2004; 44: 988-96.
11. Wannamethee SG, Shaper G, Walker M. Physical activity and mortality in older men with diagnosed coronary heart disease. Circulation 2000; 102: 1358-63.
12. Hamer M, Stamatakis E. Physical activity and mortality in men and women with diagnosed cardiovascular disease. Eur J Cardiovasc Prev Rehabil 2009; 16: 156-60.
13. Hambrecht R, Walther C, Möbius-Winkler S, et al. Percutaneous coronary angioplasty compared with exercise training in patients with stable coronary artery disease: a randomized trial. Circulation 2004; 109: 1371-8.
14. Möbius-Winkler S, Claudia Walther C, Linke A, et al. Five year follow up of the PCI vs exercise training in stable coronary artery disease-pilot trial (Pet-pilot). Circulation. 2007; 116: II_844 (abstract 3713).
15. Cutlip DE, Chhabra AG, Baim DS, et al. Beyond restenosis: five-year clinical outcomes from second-generation coronary stent tri-als. Circulation 2004; 110: 1226-30.
16. Belardinelli R, Paolini I, Cianci G, et al. Exercise training interven-tion after coronary angioplasty: the ETICA trial. J Am Coll Cardiol 2001; 37: 1891-900.
17. Giannuzzi P, Temporelli PL, Corrà U, Gattone M, Giordano A, Tavazzi L. Attenuation of unfavorable remodeling by exercise training in postinfarction patients with left ventricular dysfunction. Circulation 1997; 96: 1790-7.
18. Lavie CJ, Milani RV. Effects of nonpharmacological therapy with cardiac rehabilitation and exercise training in patients with low lev-els of high-density lipoprotein cholesterol. Am J Cardiol 1996; 78: 1286-9.
19. Lavie CJ, Milani RV. Effects of cardiac rehabilitation and exercise training on low-density lipoprotein cholesterol in patients with hy-pertriglyceridemia and coronary artery disease. Am J Cardiol 1994; 74: 1192-5.
20. Kraus WE, Houmard JA, Dusha BD, et al. Effects of the amount and intensity of exercise on plasma lipoproteins. N Engl J Med 2002; 347, 19: 1483-92.
21. Tuomilehto J, Lindstrom J, Eriksson JG, et al. Prevention of type 2 diabetes mellitus by changes in lifestyle among subjects with im-paired glucose tolerance. N Engl J Med 2001; 344: 1343-50.
22. Hu G, Jousilahti P, Barengo NC, et al. Physical activity, cardiovas-cular risk factors, and mortality among Finnish adults with diabe-tes. Diabetes Care 2005; 28: 799-805.
23. Cornelissen VA, Fagard RH. Effects of endurance training on blood pressure, blood pressure-regulating mechanisms, and cardio-vascular risk factors. Hypertension. 2005; 46: 667-75.
24. Mancia G, De Backer G, Diminiczak A, et al. 2007 Guidelines for the management of arterial hypertension The Task Force for the Management of Arterial Hypertension (ESH) and of the European Society of Cardiology (ESC). Eur Heart J 2007; 28: 1462-536.
25. Leon AS, Franklin BA, Costa F, et al. Cardiac rehabilitation and secondary prevention of coronary heart disease: an American Heart Association Scientific Statement from Council on Clinical Cardiol-ogy (Subcommittee on Exercise, Cardiac Rehabilitation, and Pre-vention and the Council on Nutrition, Physical Activity, and Me-tabolism Subcommittee on Physical Activity, in Collaboration with the American Association of Cardiovascular and Pulmonary Reha-bilitation. Circulation 2005; 111: 369-76.
26. Widlansky ME, Gokce N, Keaney JF, Vita JA. The clinical impli-cations of endothelial dysfunction. J Am Coll Cardiol 2003; 42: 1149-60.
27. Lerman A, Zeiher AM. Endothelial function. Cardiac events. Circulation 2005; 111: 363-8.
28. Fichtlscherer S, Breuer S, Zeilher AM. Prognostic value of sys-temic endothelial dysfunction in patients with acute coronary syn-dromes: further evidence for the existence of the "vulnerable" pa-tients. Circulation 2004; 110: 1926-32.
29. Kitta Y, Obata J, Nakamura T, et al. Persistent impairment of endo-thelial vasomotor function has a negative impact on outcome in patients with coronary artery disease. J Am Coll Cardiol 2009; 53: 323-30.
30. Hambrecht R, Wolf A, Gielen S, et al. Effect of exercise on coro-nary endothelial function in patients with coronary artery disease. N Engl J Med 2000; 342: 454-60.
31. Vona M, Codeluppi GM, Iannino T, Ferrari E, Bogousslavsky J, von Segesser LK. Effects of different types of exercise training fol-lowed by detraining on endothelium-dependent dilation in patients with recent myocardial infarction. Circulation 2009; 119: 1601-8.
32. Hambrecht R, Adams V, Erbs S, et al. Regular physical activity improves endothelial function in patients with coronary artery dis-ease by increasing phosphorylation of endothelial nitric oxide syn-thase. Circulation 2003; 103: 3152-8.
33. Adams V, Linke A, Kränkel N, et al. Impact of regular physical activity on the NAD(P)H oxydase and angiotensin receptor system in patients with coronary artery disease. Circulation 2005; 111: 555-62.
34. Wong LSM, de Boer RA, Samani NJ, van Veldhuisen DJ, van der Harst P. Telomere biology in heart failure. Eur J Heart Fail 2008; 11: 1049: 56.
35. Fuster JJ, Andrés V. Telomere biology and cardiovascular diseases. Circ Res 2006; 99: 1167-80.
36. Erusalimsky JD. Vascular endothelial senescence: from mecha-nisms to pathophysiology. J Appl Physiol 2009; 106: 326-32.
37. Minamino T, Komuro I. Vascular cells senescence: contribution to atherosclerosis. Circ Res 2007; 100: 15-26.
38. Chang E, Harley CB. Telomere length and replicative aging in human vascular tissues. Proc Natl Acad Sci USA 1995; 92: 11190-4.
39. Minamino T, Miyauchi H, Yoshida T, Ishida Y, Yoshida H, Komuro I. Endothelial cell senescence in human atherosclerosis. Role of telomere in endothelial dysfunction. Circulation 2002; 105: 1541-4.
40. Okuda K, Khan Y, Skurnick J, Kimura M, Aviv H, Aviv A. Te-lomere attrition of the human abdominal aorta: relationships with age and atherosclerosis. Atherosclerosis 2000; 152: 391-8.
41. Ogami M, Ikura Y, Ohsawa M, et al. Telomere shortening in hu-man coronary artery disease. Arterioscler Thromb Vasc Biol 2004; 546-50.
42. Mallat Z, Benamer H, Hugel B, et al. Elevated levels of shed mem-brane microparticles with procoagulant potential in the peripheral circulating blood of patients with acute coronary syndromes. Circu-lation 2000; 101: 841-3.
43. Benetos A, Gardner JP, Zureik M, et al. Short telomeres are associ-ated with increased carotid atherosclerosis in hypertensive subjects. Hypertension 2004; 43: 182-5.
44. Yang Z, Huang X, Jiang H, et al. Short telomeres and prognosis of hypertension in a Chinese population. Hypertension 2009; 53: 639-45.
45. Brouilette S, Singh RK, Thompson JR, Goodall AH, Samani NJ. White cell telomere length and risk of premature myocardial infarc-tion. Arterioscler Thromb Vasc Biol 2003; 23: 842-6.
46. Brouilette SW, Moore JS, McMahon AD, et al. Telomere length, risk of coronary heart disease, and statin treatment in the West of Scotland Primary Prevention Study: a nested case-control study. Lancet 2007; 369: 107-14.
47. Brouilette SW, Whittaker A, Stevens SE, van der Harst P, Goodall AH, Samani NJ. Telomere length is shorter in healthy offspring of subjects with coronary artery disease: support for the telomere hy-pothesis. Heart 2008; 94: 422-5.
48. Cawthon RM, O'Brien E, Sivatchenko A, Kerber RA. Association between telomere lengths in blood and mortality in people aged 60 years or older. Lancet 2003; 361: 393-5.
49. Werner C, Hanhoun M, Widmann T, et al. Effects of physical exercise on myocardial telomere-regulating proteins, survival pathways, and apoptosis. J Am Coll Cardiol 2008; 52: 470-82
50. Ludlow AT, Zimmerman JB, Witkowski S, Hearn JW, Hatfield BD. Relationship between physical activity level, telomere length, and telomerase activity. Med Sci Sports Exerc 2008; 1764-70.
51. Cherkas LF, Hunkin JL, Kato BS, et al. The association between physical activity in leisure time and leukocyte telomere length. Arch Intern Med 2008; 168: 154-8
52. Liao R, Pfister O, Jain M, Mouquet F. The bone marrow-cardiac axis of myocardial regeneration. Prog Cardiovasc Dis 2007; 50: 18-30.
53. Adams B, Xiao Q, Xu Q. Vascular progenitor cells and atheroscle-rosis. Future Cardiol 2007; 3: 635-45.
54. Möbius-Winkler S, Höllriegel R, Schuler G, Adams V. Endothelial progenitor cells: implications for cardiovascular disease. Cytometry 2009; 75A: 25-37.
55. Schmidt-Lucke C, Rössig L, Fichtlscherer S, et al. Reduced num-ber of circulating endothelial progenitor cells predicts future car-diovascular events: proof of concept for the clinical importance of endogenous vascular repair. Circulation 2005; 111: 2981-7.
56. Fadini GP, Agostini C, Sartore S, Avogaro A. Endothelial progeni-tor cells in the natural history of atherosclerosis. Atherosclerosis 2007; 194: 46-54.
57. Shantsila E, Watson T, Lip GYH. Endothelial progenitor cells in cardiovascular disorders. J Am Coll Cardiol 2007; 49:741-52.
58. Urbich C, Dimmeler S. Endothelial progenitor cells: characteriza-tion and role in vascular biology. Circ Res 2004; 95: 343-53.
59. Hill JM, Zalos GRN, Julian PJ, et al. Circulating endothelial pro-genitor cells, vascular function, and cardiovascular risk. N Engl J Med 2003; 348: 593-600.
60. Fadini GP, Coracina A, Baesso I, et al. Peripheral blood CD34+KDR+ endothelial progenitor cells are determinants of sub-clinical atherosclerosis in a middle-aged general population. Stroke 2006; 37: 2277-82.
61. Lau KK, Chan YH, Yiu KH, et al. Burden of carotid atherosclero-sis in patients with stroke: relationship with circulating endothelial progenitor cells and hypertension. J Hum Hypertens 2007; 21: 445-51.
62. Werner N, Kosiol S, Schiegl T, et al. Circulating endothelial pro-genitor cells and cardiovascular outcomes N Engl J Med 2005; 353: 999-1007.
63. Kunz GA, Liang G, Cuculoski F, et al. Circulating endothelial progenitor cells predict coronary artery disease severity. Am Heart J 2006; 152: 190-5.
64. Pompilio G, Capogrossi MC, Pesce M, et al. Endothelial progenitor cells and cardiovascular homeostasis: clinical implications. Int J Cardiol 2009; 131: 156-67.
65. Steiner S, Niessner A, Ziegler S, et al. Endurance training increases the number of endothelial progenitor cells in patients with cardio-vascular risk and coronary artery disease Atherosclerosis 2005; 181: 305-10.
66. Laufs U, Werner N, Link A, et al. Physical training increases endo-thelial progenitor cells, inhibits neointima formation, and enhances angiogenesis. Circulation 2004; 109: 220-6.
67. Sandri M, Adams V, Gielen S, et al. Effects of exercise and ische-mia on mobilization and functional activation of blood-derived progenitor cells in patients with ischemic syndromes: results of 3 randomized studies. Circulation 2005; 111: 3391-9.
68. Szmitko PE, Fedak PWM, Weisel RD, Stewart DJ, Kutryk MJB, Verma S. Endothelial progenitor cells. New hope for a broken heart. Circulation 2003; 107: 3093-100.
69. Crosby JR, Kaminski WE, Schatteman G, et al. Endothelial cells of hematopoietic origin make a significant contribution to adult blood vessel formation. Circ Res 2000; 87: 728-30.
70. Luk T-H, Dai Y-L, Siu C-W, et al. Habitual physical activity is associated with endothelial function and endothelial progenitor cells in patients with stable coronary artery disease. Eur J Cardio-vasc Prev Rehabil 2009; 16: 464-71.
71. Hansson GK. Inflammation, atherosclerosis, and coronary artery disease. N Engl J Med 2005; 352: 1685-95.
72. Biasucci LM. Clinical use of inflammatory markers in patients with cardiovascular diseases. Circulation 2004; 110: e560-e7.
73. Milazzo D, Biasucci LM, Luciani N, et al. Elevated levels of C-reactive protein before coronary artery bypass grafting predict re-currence of ischemic events. Am J Cardiol 1999; 84: 459-61.
74. Zouridakis E, Avanzas P, Arroyo-Espliguero R, FredericksS, Kaski JC. Markers of inflammation and rapid coronary artery disease progression in patients with stable angina pectoris. Circulation 2004; 110: 1747-53.
75. Verma S, Buchanan MR, Anderson TJ. Endothelial function testing as a biomarker of vascular disease. Circulation 2003; 108: 2054-9.
76. Kasapis C, Thompson PD. The effects of physical activity on se-rum C-reactive protein and inflammatory markers: a systematic re-view. J Am Coll Cardiol 2005; 45:1563-9.
77. Milani RV, Lavie CJ, Mehra MR. Reduction in C-reactive protein through cardiac rehabilitation and exercise training. J Am Coll Cardiol 2004; 43: 1056-61.
78. Mora S, Cook N, Buring JE, Ridker PM, Lee I-M. Physical activity and reduced risk of cardiovascular events: potential mediating mechanisms. Circulaton 2007; 116: 2110-8.
79. Imhof A, Koenig W. Exercise and thrombosis. Cardiol Clin 2001; 19: 389-400.
80. Lee KW, Lip GYH. Effects of lifestyle on hemostasis, fibrinolysis, and platelet reactivity: a systematic review. Arch Intern Med 2003; 163: 2368-92.
81. Smith DT, Hoetzer GL, Greiner JJ, Stauffer BL, DeSouza CA. Effects of ageing and regular aerobic exercise on endothelial fibri-nolytic capacity in humans. J Physiol 2003; 546: 289-98.
82. Church TS, Lavie CJ, Milani RV, Kirby GS. Improvements in blood rheology after cardiac rehabilitation and exercise training in patients with coronary heart disease. Am Heart J 2002; 143: 349-55.
83. Bigger JT, Jr, Fleiss JL, Steinman RC, Rolnitzky LM, Kleiger RE, Rottman JN. Frequency domain measures of heart period variabil-ity and mortality after myocardial infarction. Circulation 1992; 85: 164-71.
84. LaRovere MT, Bigger JT, Jr, Marcus FI, Mortara A, Schwartz PJ. Baroreflex sensitivity and heart rate variability in prediction of total cardiac mortality after myocardial infarction. Lancet 1998; 351: 478-84.
85. Billman GE. Aerobic exercise conditioning: a nonpharmacologic antiarrhythmic intervention. J Appl Physiol 2002; 92: 446-54.
86. Iellamo F, Legramante JM, Massaro M, Raimondi G, Galante A. Effects of a residential exercise training on baroreflex sensitivity and heart rate variability in patients with coronary artery disease: a randomized, controlled study. Circulation 2000; 102: 2588-92.
87. Malfatto G, Facchini M, Sala L, Branzi G, Bragato R, Leonetti G. Effects of cardiac rehabilitation and betablocker therapy on heart rate variability after first acute myocardial infarction. Am J Cardiol 1998; 81: 834-40.
88. LaRovere MT, Bersano C, Gemmi M, et al. Exercise-induced increase in baroreflex sensitivity predicts improved prognosis after myocardial infarction Circulation 2002; 106: 945-9.
89. Shepard RJ, Balady GJ. Exercise as cardiovascular therapy. Circu-lation 1999; 99: 963-72.
90. Belardinelli R, Georgiou D, Ginzton L, Cianci G, Purcaro A. Ef-fects of moderate exercise training on thallium uptake and contrac-tile response to low-dose dobutamine of dysfunctional myocardium in patients with ischemic cardiomyopathy. Circulation 1998; 97: 553-61.
91. Domenech RJ. Preconditioning: a new concept about the benefit of exercise. Circulation 2006; 113: e1-e3.
92. Yusuf S, Hawken S, Ôunpuu S, et al. Effect of potentially modifi-able risk factors associated with myocardial infarction in 52 coun-tries (the INTERHEARTstudy):case-control study. Lancet 2004; 364: 937-52.
93. Rea TD, Heckbert SR, Kaplan RC, Smith NL, Lemaitre RN, Psaty BM. Smoking status and risk for recurrent coronary events after myocardial infarction. Ann Intern Med 2002; 137(6): 494-500.
94. Rallidis LS, Panagiotakos DB, Pitsavos C, Stefanadis C, Kremasti-nos DT. Persistent smokers after myocardial infarction: a group that requires special attention. Int J Cardiol 2005; 100(2): 241-5.
95. Taira DA, Seto TB, Ho KK, et al. Impact of smoking on health-related quality of life after percutaneous coronary revascularization. Circulation 2000; 102:1369-74.
96. Ambrose JA, Barua RS. The pathophysiology of cigarette smoking and cardiovascular disease: an update. J Am Coll Cardiol 2004; 43: 1731-7.
97. Czernin J, Waldherr C. Cigarette smoking and coronary blood flow. Prog Cardiovasc Dis 2003; 45: 395-404.
98. Hosokawa S, Hiasa Y, Miyazaki S, et al. Effects of smoking on coronary endothelial function in patients with recent myocardial in-farction. Int J Cardiol 2008; 128: 48-52.
99. Burke AP, Farb A, Malcom GT, Liang Y, Smialek J, Virmani R. Coronary risk factors and plaque morphology in men with coronary disease who died suddenly. N Engl J Med 1997; 336: 1276-82.
100. [100] Shah PK. Mechanisms of plaque vulnerability and rupture. J Am Coll Cardiol 2003; 41: 15S-22S.
101. Virmani R, Kolodgie FD, Burke AP, Farb A, Schwartz SM. Les-sons from sudden coronary death: a comprehensive morphological classification scheme for atherosclerotic lesions. Arterioscler Thromb Vasc Biol 2000; 20: 1262-75.
102. Vasa M, Fichtlscherer S, Aicher A, et al. Number and migratory activity of circulating endothelial progenitor cells inversely corre-lates with risk factors for coronary artery disease. Circ Res 2001; 89: e1-e7.
103. Newby DE, Wright RA, Labinjoh C, et al. Endothelial dysfunction, impaired endogenous fibrinolysis, and cigarette smoking: a mecha-nism for arterial thrombosis and myocardial infarction. Circulation 1999; 99: 1411-5.
104. Matetzky S, Tani S, Kangavari S, et al. Smoking increases tissue factor expression in atherosclerotic plaques implications for plaque thrombogenicity. Circulation 2000; 102: 602-4.
105. Benowitz NL, Gourlay SG. Cardiovascular toxicity of nicotine: implications for nicotine replacement therapy. J Am Coll Cardiol 1997; 29: 1422-31.
106. Wilson K, Gibson N, Willan A, Cook D. Effect of smoking cessa-tion on mortality. Meta-analysis of cohort studies. Arch Int Med 2000; 160: 939-44.
107. Critchley JA, Capewell S. Mortality risk reduction associated with smoking cessation in patients with coronary heart disease. JAMA 2003; 290: 86-97
108. Voors AA, Van Brussel BL, Plokker T, et al. Smoking and cardiac events after venous coronary bypass surgery. Circulation 1996; 93: 42-7.
109. van Domburg RT, Scholte op Reimer W, Hocks SE, Kappetein AP, Bogers JJC. Three life-years gained from smoking cessation after coronary artery bypass surgery: a 30-year follow-up study. Am Heart J 2008; 156: 473-6.
110. Hasdai D, Garrat KN, Grill DE, Lerman A, Holmes DR, Jr. Effect of smoking status on the long-term outcome after successful percu-taneous coronary revascularization. N Engl J Med 1997; 336: 755-61.
111. Cardiologists should be less passive about smoking cessation. Lancet 2009; 373: 867.
112. Ockene IS, Houston MN, For the American Heart Association Task Force on Risk Reduction. Cigarette smoking, cardiovascular dis-ease, and stroke: a statement for healthcare professionals from the American Heart Association. Circulation 1997; 96: 3243-7.
113. Ockene J, Kristeller JL, Goldberg R, et al. Smoking cessation and severity of disease: the Coronary Artery Smoking Intervention Study. Health Psychol 1992; 11: 119-26.
114. Dawood N, Vaccarino V, Reid KJ, Spertus JA, Hamid N, Parashar S. Predictors of smoking cessation after a myocardial infarction. The role of institutional smoking cessation programs in improving success. Arch Int Med 2008; 168: 1961-7.
115. Murray EW. Smoking cessation clinical practice guideline update and agency for healthcare research and quality tobacco resources. Tobacco Control 2000; 9(Suppl I): I72-3.
116. Hu FB. Diet and lifestyle influences on risk of coronary heart dis-ease. Curr Atheroscler Rep 2009; 11: 257-63.
117. Giugliano D, Ceriello A, Esposito K. The effects of diet on in-flammation: emphasis on metabolic syndrome. J Am Coll Cardiol 2006; 48: 677-85.
118. Hu FB, Willett WC. Optimal diets for prevention of coronary heart disease. JAMA 2002; 288: 2569-78.
119. Leaf A. The electrophysiologic basis for the antiarrhythmic actions of polyunsaturated fatty acids. Eur Heart J 2001; 22: D98-D105.
120. Mente A, de Koning L, Harry S, Shannon HS, Sonia S, Anand SS. A systematic review of the evidence supporting a causal link be-tween dietary factors and coronary heart disease. Arch Intern Med 2009; 169: 659-69.
121. Barzi F, Woodward M, Marfisi RM, et al. Mediterranean diet and all-causes mortality after myocardial infarction: results from the GISSI-Prevenzione trial. Eur J Clin Nutr 2003; 57: 604-11.
122. de Lorgeril M, Salen P, Martin JL, et al. Mediterranean diet, tradi-tional risk factors and the rate of cardiovascular complications after myocardial infarction. Final report of the Lyon Diet Heart Study. Circulation 1999; 99: 779-85.
123. Burr ML, Fehily AM, Gilbert JF, et al. Effects of changes in fat, fish, and fibre intakes on death and myocardial reinfarction: Diet and Reinfarction Trial (DART). Lancet 1989; 2: 757-61.
124. GISSI-Prevenzione Investigators. Dietary supplementation with n-3 polyunsaturated fatty acids and vitamin E after myocardial infarc-tion: results from the GISSI-Prevenzione trial. Lancet 1999; 354: 447-55.
125. Marchioli R, Barzi F, Bomba E, et al. Early protection against sudden death by n-3 polyunsaturated fatty acids after myocardial infarction: time-course analysis of the results of the Gruppo Ital-iano per lo Studio della Sopravvivenza nell'Infarto Miocardico (GISSI)-Prevenzione. Circulation 2002; 105:1897-903.
126. Allison TG. Improving weight loss in cardiac rehabilitation. Circu-lation 2009; 119: 2650-2.
127. Graham I, Atar D, Borch-Johnsen K, et al. ESC Committee for Practice Guidelines. European guidelines on cardiovascular disease prevention in clinical practice: executive summary. Atherosclerosis 2007; 194: 1-45.
128. Sierra-Johnson J, Romero-Corral A, Somers VK, et al. Prognostic importance of weight loss in patients with coronary heart disease regardless of initial body mass index. Eur J Cardiovasc Prev Reha-bil 2008; 15: 336-40.
129. Ades PA, Savage PD, Toth MJ, et al. High-calorie-expenditure exercise: a new approach to cardiac rehabilitation for overweight coronary patients. Circulation 2009; 119: 2671-8.
130. Levantesi G, Macchia A, Marfisi R, et al., for the GISSI-Prevenzione Investigators. Metabolic syndrome and risk of cardio-vascular events after myocardial infarction. J Am Coll Cardiol 2005; 46: 277-83.
131. Boch BC, Carmona-Barros RE, Esler JL, Tilkemeier PL. Program participation and physical activity maintenance after cardiac reha-bilitation. Behav Modification 2003; 1: 37-53.
132. Lear SA, Spinelli JJ, Linden W, et al. The Extensive Lifestyle Management Intervention (ELMI) after cardiac rehabilitation: a 4-year randomized controlled trial. Am Heart J 2006; 152: 333-9.
133. Moore SM, Charvat JM, Gordon NH, et al. Effects of a CHANGE intervention to increase exercise maintenance following cardiac events. Ann Behav Med 2006; 31: 53-62.
134. De Velasco JA, Rodriguez JA, Ridocci F, et al. Action to improve secondary prevention in coronary artery disease patients: one-year follow-up of a shared care programme. Eur Heart J Suppl 2004; 6(Suppl J): J27-J32.
135. Giannuzzi P, Temporelli PL, Maggioni AP, et al, Global Secondary Prevention strategies to limit event recurrence after myocardial in-farction: the GOSPEL study. A trial from the italian cardiac reha-bilitation network: rationale and design. Eur J Cardiovasc Prev Re-habil 2005; 12: 555-61.
136. Giannuzzi P, Temporelli PL, Marchioli R, et al. Global secondary prevention strategies to limit event recurrence after myocardial in-farction. results of the GOSPEL study, a multicenter, randomized controlled trial from the italian cardiac rehabilitation network. Arch Intern Med 2008; 168: 2194-204.
137. Jackson L, Leclerc J, Erskine Y, Linden W. Getting the most out of cardiac rehabilitation: a review of referral and adherence predictors. Heart 2005; 91: 10-4.
138. Willich SN, Muller-Nordhorn J, Kulig M, et al. Cardiac risk fac-tors, medication, and recurrent clinical events after acute coronary disease; a prospective cohort study. Eur Heart J 2001; 22: 307-13.
139. Bock BC. Issues in predicting adherence to cardiac rehabilitation. J Cardiopulm Rehabil 2002; 22: 261-3.
140. Moore SM, Charvat JM, Gordon NH, et al. Effects of a change intervention to increase exercise maintenance following cardiac events. Ann Behav Med 2006; 31: 53-62.
141. Hawkes AL, Atherton J, Taylor CB, et al. Randomised controlled trial of a secondary prevention program for myocardial infarction patients (ProActive Heart) study protocol: secondary prevention program for myocardial infarction patients. BMC Cardiovasc Dis-ord 2009; 9: 9-16.